Clarfeld Financial Advisors’s Nektar Therapeutics NKTR Stock Holding History

Clarfeld Financial Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$1K	Buy	+1	New	+$604	﹤0.01%	497

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clarfeld Financial Advisors's NKTR Position: Q4 2018 in Review

Clarfeld Financial Advisors opened a new position in Nektar Therapeutics (NKTR) in Q4 2018: 1 share worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #497 among its holdings.

343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

Clarfeld Financial Advisors held 1 share of Nektar Therapeutics worth $1K as of Q4 2018.
Nektar Therapeutics was a new Clarfeld Financial Advisors position in Q4 2018.
Nektar Therapeutics made up ﹤0.01% of Clarfeld Financial Advisors's portfolio in Q4 2018, its #497 holding.
343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Clarfeld Financial Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.